Expression of lysyl oxidase in human osteosarcoma and its clinical significance: a tumor suppressive role of LOX in human osteosarcoma cells - PubMed (original) (raw)
Comparative Study
. 2013 Nov;43(5):1578-86.
doi: 10.3892/ijo.2013.2067. Epub 2013 Aug 21.
Affiliations
- PMID: 23970168
- DOI: 10.3892/ijo.2013.2067
Comparative Study
Expression of lysyl oxidase in human osteosarcoma and its clinical significance: a tumor suppressive role of LOX in human osteosarcoma cells
Xin Xu et al. Int J Oncol. 2013 Nov.
Abstract
Lysyl oxidase (LOX) is an extracellular matrix (ECM) remodeling enzyme, which is involved in the development and progression of many types of tumors. LOX dysfunction is observed in colorectal, breast and ovarian cancer. However, the precise effects and molecular mechanisms of LOX action in osteosarcoma progression are still unknown. We evaluated the role of LOX in human osteosarcoma cell lines and clinical tumor samples in order to determine the function of this molecule. In our study, we showed that the expression level of LOX mRNA and protein were decreased in human osteosarcoma tissues as compared with normal tissue samples. In addition, we employed adenovirus-mediated overexpression of LOX in U-2OS and HOS cells to investigate the role of LOX in osteosarcoma cell lines. Adenovirus-mediated overexpression of LOX could efficiently increase the expression levels of LOX in osteosarcoma cell lines at both mRNA and protein levels. Increased expression of LOX inhibited the proliferation and migration of human osteosarcoma cells and promoted its apoptosis. Moreover, the Ki-67 and PCNA expression was decreased and MMP-2 and MMP-9 expression was inhibited. These findings also indicated that the effects of LOX may be mediated via the PI3K/AKT signaling pathway since LOX-mediated functions could be blocked by β-aminopropionitrile (β-APN), a LOX inhibitor. Taken together, our data indicated that LOX may be a tumor suppressor and could be regarded as a therapeutic target in human osteosarcoma.
Similar articles
- The overexpression of BAMBI and its involvement in the growth and invasion of human osteosarcoma cells.
Zhou L, Park J, Jang KY, Park HS, Wagle S, Yang KH, Lee KB, Park BH, Kim JR. Zhou L, et al. Oncol Rep. 2013 Sep;30(3):1315-22. doi: 10.3892/or.2013.2569. Epub 2013 Jun 26. Oncol Rep. 2013. PMID: 23807684 - Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Chen LC, Tu SH, Huang CS, Chen CS, Ho CT, Lin HW, Lee CH, Chang HW, Chang CH, Wu CH, Lee WS, Ho YS. Chen LC, et al. Breast Cancer Res Treat. 2012 Aug;134(3):989-1004. doi: 10.1007/s10549-012-1986-8. Epub 2012 Mar 21. Breast Cancer Res Treat. 2012. PMID: 22434522 - Expression of the lysyl oxidase propeptide in hepatocellular carcinoma and its clinical relevance.
Zheng Y, Wang X, Wang H, Yan W, Zhang Q, Chang X. Zheng Y, et al. Oncol Rep. 2014 Apr;31(4):1669-76. doi: 10.3892/or.2014.3044. Epub 2014 Feb 20. Oncol Rep. 2014. PMID: 24573150 - Paradoxical roles for lysyl oxidases in cancer--a prospect.
Payne SL, Hendrix MJ, Kirschmann DA. Payne SL, et al. J Cell Biochem. 2007 Aug 15;101(6):1338-54. doi: 10.1002/jcb.21371. J Cell Biochem. 2007. PMID: 17471532 Review. - Lysyl Oxidase and the Tumor Microenvironment.
Wang TH, Hsia SM, Shieh TM. Wang TH, et al. Int J Mol Sci. 2016 Dec 29;18(1):62. doi: 10.3390/ijms18010062. Int J Mol Sci. 2016. PMID: 28036074 Free PMC article. Review.
Cited by
- Pediatric cancer-pathology and microenvironment influence: a perspective into osteosarcoma and non-osteogenic mesenchymal malignant neoplasms.
Sergi CM. Sergi CM. Discov Oncol. 2024 Aug 18;15(1):358. doi: 10.1007/s12672-024-01240-5. Discov Oncol. 2024. PMID: 39154307 Free PMC article. Review. - Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K/Akt pathway.
Zhu J, Sun Y, Lu Y, Jiang X, Ma B, Yu L, Zhang J, Dong X, Zhang Q. Zhu J, et al. Cell Death Dis. 2018 Jun 13;9(6):708. doi: 10.1038/s41419-018-0684-9. Cell Death Dis. 2018. PMID: 29899333 Free PMC article. - LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome.
Hua YJ, Wang HY, Tang LQ, Chen QY, Shao JY, Mai HQ. Hua YJ, et al. Oncotarget. 2016 Feb 16;7(7):8200-7. doi: 10.18632/oncotarget.6996. Oncotarget. 2016. PMID: 26882568 Free PMC article. - Lysyl oxidase mediates hypoxia-induced radioresistance in non-small cell lung cancer A549 cells.
Gong C, Gu R, Jin H, Sun Y, Li Z, Chen J, Wu G. Gong C, et al. Exp Biol Med (Maywood). 2016 Feb;241(4):387-95. doi: 10.1177/1535370215609694. Epub 2015 Oct 28. Exp Biol Med (Maywood). 2016. PMID: 26515140 Free PMC article. - Sarcoma Tumor Microenvironment.
Tsagozis P, Gonzalez-Molina J, Georgoudaki AM, Lehti K, Carlson J, Lundqvist A, Haglund F, Ehnman M. Tsagozis P, et al. Adv Exp Med Biol. 2020;1296:319-348. doi: 10.1007/978-3-030-59038-3_20. Adv Exp Med Biol. 2020. PMID: 34185302
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous